|Year : 2007 | Volume
| Issue : 1 | Page : 31-35
Cytotoxic drug: Towards safer chemotherapy practices
Clinical Pharmacologist, Prescription Audit Department, Indraprastha Apollo Hospital, Delhi Mathura Road, Sarita Vihar, New Delhi - 110 076, India
M C Joshi
Clinical Pharmacologist, Prescription Audit Department, Indraprastha Apollo Hospital, Delhi Mathura Road, Sarita Vihar, New Delhi - 110 076
Source of Support: None, Conflict of Interest: None
Health care is nearly 10 years behind other industries in its efforts to reduce the errors. Medication error may be nobody's baby, but when it happens, it could well turn out to be everyone's worry and the reasons given for medication error range from silly to the downright serious. The anticancer drugs are known to be mutagenic, teratogenic and carcinogenic, so extra precaution should be taken while storing, diluting, administering the drugs and disposing the waste. The objectives of this article are to define the standards for using cancer chemotherapy in hospitals; to tackle any spillage of drug and how to dispose of the waste of anticancer drugs. This could be beneficial to any hospital where chemotherapy is given without any defined standard operating procedure. The information furnished in this article is collected from the mentioned references and also from websites- The American Cancer Society: Cancer Facts and Figures 2002, www.cancer.org and www.cancersourceRN.com
Keywords: Carcinogenic, mutagenic, teratogenic
|How to cite this article:|
Joshi M C. Cytotoxic drug: Towards safer chemotherapy practices. Indian J Cancer 2007;44:31-5
| » Introduction|| |
The problem of medication safety came to public attention largely through a chemotherapy error and the high toxicity and low therapeutic index of anticancer medications make safety in their prescription and administration critical. The anti cancer drugs are known to be mutagenic, teratogenic and carcinogenic therefore all efforts must be done to reduce accidents from cancer chemotherapy and to implement safe chemotherapy practices.
| » Safe Chemotherapy Practices Program|| |
The problem of medical errors came to focus a decade back because of certain noticeable accidents such as the death of Boston Globe medical writer Betsy Lehman, 12 years ago due to an overdose of chemotherapy. Oncologists have no greater or lesser chance of erring than most other physicians, but the high toxicity and small therapeutic index of the drugs they prescribe make chemotherapy errors potentially catastrophic. After the Lehman incident, many hospitals and practices examined their chemotherapy ordering practices and put new safeguards in place and a vast majority of comprehensive cancer centers, university hospitals and community hospitals had begun chemotherapy safety programs.
| » Prescription of Cytotoxic Drugs|| |
The cytotoxic drug order by the oncologist is sent to the pharmacy at least one hour in advance of the anticipated administration time. These orders contain all the relevant hand written information regarding the drug (brand and generic name, cost, rate and route of administration, diluents to be used, filter to be used) and are labeled as chemotherapy order sheet. These prescription orders in some hospitals are sent to the pharmacist using computer software to reduce the chances of transcription errors, but still in many hospitals in India they are hand written. The cytotoxic drug prescription should contain all the relevant information regarding the drug, the doses according to body wt or body surface area (BSA), the diluents to be used, infusion rate, route of administration, the diagnosis of the patient. All doses should be calculated independently by the physician, the pharmacist and the nurse. Dosage limits should be established and a review process set up for doses that exceed the limits. These limits should be entered into the pharmacy computer systems, listed on preprinted order forms, stated on the product packaging, placed in strategic locations in the institution and communicated to employees.
Now days computerized software programmes are available to reduce the errors of transcription. This software calculates the appropriate doses once weight/BSA or other relevant information of the patient is fed and also raise alarms in case wrong infusion fluid or rate or IV line filter is used.
| » Validation of Prescription by a Pharmacist|| |
An onco-pharmacist is responsible for checking the rationality of chemo-medication ordered by the consultants. The onco-pharmacist checks the chemotherapy order for right diluents, right doses and right route of administration. He reviews the profiles of the patients and verifies that all labels are written correctly. A second pharmacist shall verify that the order has been profiled and entered into the computer correctly and shall initial the profile to the left of the drug name. Medication errors are common to occur if cross checks are not done regularly and while most such errors have little potential for harm they cause substantial extra work in hospitals. A small proportion do have the potential to cause injury and some cause preventable adverse drug events. Some studies suggest computerized physician order entry (POE) with decision support to decrease the rate of non-missed-dose medication errors.
Although information technologies are widely used in hospitals, relatively few data are available regarding their impact on the safety of the process of giving drugs. Exceptions are computerized physician order entry and computerized physician decision support, which have been found to improve drug safety.,,
Computerized POE is an application in which physicians write orders online. This system has probably had the largest impact of any automated intervention in reducing medication errors; the rate of serious errors fell 55% in one study and the rate of all errors fell 83% in another. Computerization of ordering improves safety in several ways: firstly, all orders are structured, so that they must include a dose, route and frequency; secondly, they are legible and the orderer can be identified in all instances; thirdly, information can be provided to the orderer during the process; and fourthly, all orders can be checked for a number of problems including allergies, drug interactions, overly high doses, drug-laboratory problems (giving a patient a drug when they have a known biochemical factor that predisposes them to risk) and whether the dose is appropriate for the patient's liver and kidney function. Other innovations, which include using robots to fill prescriptions, bar coding, automated dispensing devices and computerization of the medication administration record, though less studied, should all eventually reduce error rates.
These orders have to be prepared as soon as possible. If a drug is needed immediately and no pharmacist is available to make the admixture, then a duty doctor / nurse of oncology department may use the pharmacy hood to prepare the admixture. The anticipated administration time shall clearly be indicated on the pharmacy copy of the physician order. A Checklist before preparing the cytotoxic drugs is made which is called the chemotherapy order sheet.
This chemotherapy order sheet includes the following things:
- Name of the drug, company name, active salt, strength and expiry date
- Patient name, age and patient ID number
- Number of chemotherapy cycle
- Approximate cost of the drug
- Drug delivery route and access devices
- Solvent and its concentration in which it is to be mix
- Infusion or diluents fluids (D5%W / NS / RL / DNS) with which to be mixed
- Availability of drug delivery access
- Cross marking of the pack and label of the vial / ampoule
- Premedication as prescribed is given
- Drug dose according to body surface area / body weight
| » Procedures of Safe Cytotoxic Drug Reconstitution|| |
Cytotoxic drug dilution is an important part of cancer chemotherapy. It should be carried out separately in a cytotoxic admixture unit and not in the wards because of the danger from spillage and contamination. Class II cabinets are the recommended safety cabinets for drug dilution under laminar flow. Class II cabinets are part-recirculation laminar airflow enclosures with HEPA filtration of exhaust air and an air barrier at the work opening. Separate fan/HEPA filter systems are provided for exhaust and laminar air flow. Cytotoxic drug safety cabinets are similar to class II cabinets in terms of operator and product protection. They also overcome the problem of protecting maintenance personnel by locating the exhaust filter under the work surface. They provide environmental and product protection.
Precautions during dilution of cytotoxic drugs
All precautions must be taken to reduce direct contact whether through skin exposure, inhalation or ingestion. Adequate facilities for drug preparation are essential to reduce the risk of exposure. The following points are important.,,,
- Wear latex powder free long cuff gloves while preparing chemotherapy drugs. Wear a gown that is low or non-permeable, long sleeve, cuffed and solid fronted and use aerosols free mask.
- Work over a suitable container to prevent the spread of any spillage.
- Prevent high pressure being generated inside sealed vials - when fluids are introduced an equivalent volume of air should be withdrawn or a venting needle with a hydrophobic filter (to prevent aerosol formation) may be used if available.
- Ampoules should be directed away from the face and covered with a suitable pad or cotton when broken open.
- Diluent fluids should be introduced slowly into open-ended ampoules or vials, running it down the vessel wall and ensuring the drug powder is moist before shaking.
- When excess air is expelled from a filled syringe it should be exhausted into a pad and not straight into the atmosphere.
- If excess drug is to be expelled from a filled syringe it should be removed first and sterile cotton wool placed over the end of the syringe to prevent possible scatter of aerosol droplets.
- Luer lock fittings should be used on syringes, tubing and I.V. sets.
- Label all prepared bottles (It is mandatory).
- Admix all cytotoxic drugs in class II biological safety cabinet (laminar air flow) that meets standards and it is inspected appropriately.
- Check the reconstitute or diluents for the particular drug and the concentration in which it is reconstituted.
- The cytotoxic drug after reconstitution should be administered as soon as possible. Before reconstitution it should be stored at cold refrigerator temperature of 2-8oC (36oF - 46oF) or controlled room temperature of 15-30oC (59-86oF) depending on the product. Protect from light. After reconstitution with the provided or appropriately selected diluents always store at cold refrigerator temperature of 2-8oC (36oF - 46oF). Do not refrigerate the reconstituted product. The duration of stability after reconstitution varies with chemical composition of the compound but usually if stored at cold refrigerator temperature of 2-8oC (36oF - 46oF) the reconstituted product is stable for at least 24h.
Administration of cytotoxic drugs in the ward or outpatients
The practice of preparing cytotoxic drug in the wards or outpatients should be discouraged because of the danger of spillage and higher chances of exposure of the personnel involved in preparing. If a drug is needed immediately and no pharmacist is available to make the admixture, then a duty doctor / nurse of oncology department may use the pharmacy hood to prepare the admixture. If however a cytotoxic admixture unit is not established in a hospital then in the wards or outpatients a proper place should be fixed and all the precautionary measures to avoid exposure like wearing latex powder free long cuff gloves, a gown that is low or non-permeable, long sleeve, cuffed and solid fronted, aerosols free mask. A spillage kit should be kept near by to tackle the cytotoxic drug spillage.
Management of spillage of cytotoxic drugs,,,,
The spillage of cytotoxic drugs should be handled with utmost care. A proper procedure must be implemented for spillage and it should be treated appropriately. On spillage of cytotoxic drugs on body parts an appropriate treatment should be given according to [Table - 1],[Table - 2]. The admixture room should have a spill kit with the following items:
- Phosphate buffer pH 7.4 9. Powder free gloves - 2 pairs
- DMSO (dimethylsulfoxide) 100% 10. Aerosols free mask and head cap - 1
- Hypochlorite ointment FNA 0.25% 11. Absorbent towel - 2, 12"x12"
- Sodium thiosulphate 10% 12. Scoop and brush - 1 set
- Sodium carbonate solution 3% 13. Eye glass - 1
- Sodium hypochlorite 5% 14. Cytotoxic disposal poly bag - 1
- 0.1N hydrochloric acid 15. Gown poly coated - 1
- Alcohol 70% 16. Shoe covers - 1 pair
Disposal of waste materials
The waste material generated after cytotoxic drug admixing like syringe, needle, mask and gloves should be disposed carefully in cytotoxic disposal bags. A standard procedure is to be made and followed for disposals of waste materials. The disposal bags should print with cytotoxic drug.
Cytotoxic waste is highly hazardous and should never be land filled or discharged into the sewerage system. Disposal options include the following.
- Return to original supplier: This is currently the preferred option for countries that lack the facilities for incineration.
- Incineration at high temperatures: Modern double-chamber pyrolytic incinerators are suitable, provided that a temperature of 1200°C with a minimum gas residence time of 2 seconds or 1000°C with a minimum gas residence time of 5 seconds can be achieved in the second chamber. The incinerator should be fitted with gas cleaning equipment.
- Chemical degradation: Most of these methods are relatively simple and safe; they include oxidation by potassium permanganate (KMnO4) or sulphuric acid (H2SO4), denitrozation by hydro bromic acid (HBr) or reduction by nickel and aluminium. The International Agency for Research on Cancer (IARC) (Unit of Gene-Environment Interactions, 150 Cours Albert-Thomas, 69372 Lyon Cedex 08, France) may be contacted for further information.
Maintenance of records and incident forms
The hospital should maintain the records of patients receiving cytotoxic drugs. Every detail regarding the cytotoxic drug used and how it was prepared etc. Incident form should be filled in case of any error in the process. Any spillage of the cytotoxic drugs is notified.
Audit of the cytotoxic drugs usage
The whole process of cytotoxic drug admixture and administration should be handled very carefully because any error occurring in the process is bound to be a serious one. Periodic review of cytotoxic drugs administration practices, as well as an analysis of any error committed, is necessary to develop optimal patient care. There are reports of using rapid cycle change method, which could be helpful in driving out fear and a fair reporting of errors and learning from them. Every institution should have a quality assurance and audit plan in place which details the process for responding when an error has been made and methods for counseling the health care providers involved. Committees formed to address these issues should include representatives of all disciplines involved in medication ordering, preparation and administration.
| » Conclusion|| |
This review study focuses on the important aspect of safe chemotherapy practices, which not only includes safe handling, proper dilution and dispensing in cytotoxic admixture unit, but also the management of any spillage of cytotoxic drugs in the hospital and disposal of the biohazardous waste generated by the use of cytotoxic drugs. Since, these drugs have a high toxicity an utmost care and precautions is to be taken while handling preparing, administering and disposing.
| » References|| |
|1.||Womer RB, Tracy E, Soo-Hoo W, Bickert B, DiTaranto S, Barnsteiner JH. Multidisciplinary systems approach to chemotherapy safety: Rebuilding processes and holding the gains. J Clin Oncol 2002;20:4705-12. [PUBMED] [FULLTEXT]|
|2.||Dinning C, Branowicki P, O'Neill JB, Marino BL, Billett A. Chemotherapy error reduction: A multidisciplinary approach to create templated order sets. J Pediatr Oncol Nurs 2005;22:20-30. [PUBMED] [FULLTEXT]|
|3.||Cohen MR. Anderson RW, Attilio RM, Green L, Muller RJ, Pruemer JM. Preventing medication errors in cancer chemotherapy. Am J Health Syst Pharm 1996;53:737-46. |
|4.||Bates DW, Teich JM, Lee J, Seger D, Kuperman GJ, Ma'Luf N, et al . The impact of computerized physician order entry on medication error prevention. J Am Med Inform Assoc 1999;6:313-21. [PUBMED] [FULLTEXT]|
|5.||Bates DW. Using information technology to reduce rates of medication errors in hospital. BMJ 2000;320:788-91. [PUBMED] [FULLTEXT]|
|6.||Bates DW, Leape LL, Cullen DJ, Laird N, Petersen LA, Teich JM, et al . Effect of computerized physician order entry and a team intervention on prevention of serious medication errors. JAMA 1998;280:1311-6. [PUBMED] [FULLTEXT]|
|7.||Vanderbroncke J, De Cock P, Robays H. Influence of a computerized program on the quality of prescribing and preparing cytotoxic drugs. J Oncol Pharm Practice 2004;10:61. |
|8.||Wick C, Slawson MH, Jorgenson JA, Tyler LS. Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Am J Health Syst Pharm 2003;60:2314-20. [PUBMED] [FULLTEXT]|
|9.||Oncology nursing society: ONS cancer chemotherapy guidelines and recommendations for practice. Oncology Nursing Society Press: Pittsburgh; 1999. |
|10.||Rutherford C. Position paper-Administration of antineoplastic agents. J Intraven Nurs 1992;15:8-9. [PUBMED] |
|11.||ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm 1990;47:1033-49. |
|12.||American society of hospital pharmacists: Safe handling of cytotoxic and hazardous drugs study guide. American Society of Hospital Pharmacists: Bethesda MD; 1990. |
|13.||Vandenbroucke J, Robays H. How to protect environment and employees against cytotoxic agents the ghent experience. J Oncol Pharm Practice 2001;6:146-52. |
|14.||Kiffmeyer TK, Kube C, Opiolka S. Vapour pressure, evaporation behavior and air borne concentration of hazardous drugs: Implication for occupational safety. Pharm J 2000;268:331-7. |
|15.||Sessink PJ, Wittenhorst BC, Anzion RB, Rob RP. Exposure of pharmacy technicians to antineoplastic agents: Reevaluation after additional protective measures. Arch Environ Health 1997;52:240-4. |
|16.||Safe management of wastes from health care activities. WHO: 1999. Available from: http://www.who.int/cytotoxic waste management. |
[Table - 1], [Table - 2]
|This article has been cited by|
||Impact of computerised physician order entry (CPOE) on the incidence of chemotherapy-related medication errors: a systematic review
| ||Suresh Kumar Srinivasamurthy, Ramkumar Ashokkumar, Sunitha Kodidela, Scott C. Howard, Caroline Flora Samer, Uppugunduri Satyanarayana Chakradhara Rao |
| ||European Journal of Clinical Pharmacology. 2021; 77(8): 1123 |
|[Pubmed] | [DOI]|
||How human activity impacted manufacturing non-compliances: A multivariate analysis in a centralized cytotoxic preparation unit
| ||Lucie Cornet, Caroline Gervaise, Marion Hugues, Sandrine Menguy, Agnès Macé, Fabien Tinquaut, Fabien Forges, Xavier Simoens |
| ||Journal of Oncology Pharmacy Practice. 2020; : 1078155220 |
|[Pubmed] | [DOI]|
||Infusional Chemotherapy and Medication Errors in a Tertiary Care Pediatric Cancer Unit in a Resource-limited Setting
| ||Mayank Dhamija,Gauri Kapoor,Atul Juneja |
| ||Journal of Pediatric Hematology/Oncology. 2014; 36(7): e412 |
|[Pubmed] | [DOI]|
||Nephroprotector activity of hydro alcoholic extract of Tinospora cordifolia roots on cisplatin induced nephrotoxicity in rats
| ||Spandana Uppuluri,Shaik Liakhat Ali,Thota Nirmala,Markapudi Shanthi,Babu Sipay,Kiran Babu Uppuluri |
| ||Drug Invention Today. 2013; |
|[Pubmed] | [DOI]|
||Mutagenic evaluation of combined paclitaxel and cisplatin treatment in somatic cells of Drosophila melanogaster
| ||Cristiane Cademartori Danesi,Bruno Corrêa Bellagamba,Rafael Rodrigues Dihl,Heloísa Helena Rodrigues de Andrade,Kênya Silva Cunha,Mário Antônio Spanó,Maria Luíza Reguly,Mauricio Lehmann |
| ||Mutation Research/Genetic Toxicology and Environmental Mutagenesis. 2010; 696(2): 139 |
|[Pubmed] | [DOI]|
||Mutagenic evaluation of combined paclitaxel and cisplatin treatment in somatic cells of Drosophila melanogaster
| ||Danesi, C.C., Bellagamba, B.C., Dihl, R.R., de Andrade, H.H.R., Cunha, K.S., Spanó, M.A., Reguly, M.L., Lehmann, M. |
| ||Mutation Research - Genetic Toxicology and Environmental Mutagenesis. 2010; 696(2): 139-143 |